Full Breakdown
FDA Leadership Turmoil: Makary Resignation and Hoeg’s Exit Signal Deepening Shakeup
5/16/2026, 5:17:39 AM
Leadership Turnover at the FDA
Acting CDER head Tracy Beth Hoeg will depart days after Commissioner Marty Makary submitted his resignation, ending Hoeg’s five-month tenure and Makary’s 13-month term. Deputy director Michael Davis will assume CDER leadership; deputy commissioner Kyle Diamantas will serve as acting FDA commissioner.
Political and Policy Context
The exits occur as the White House, led by President Donald Trump and HHS Secretary Robert F. Kennedy Jr., tightens control of the department. Recent battles over a reduced childhood vaccine schedule, fruit-flavored e-cigarettes, and a generic mifepristone have placed Makary and Hoeg at the center of partisan disputes.
Key Figures & Groups
Marty Makary, a surgeon-researcher, led the FDA through mass layoffs and policy clashes. Tracy Beth Hoeg, an epidemiologist, directed CDER and pushed safety reviews of RSV and a Sanofi diabetes drug. HHS spokesperson Emily Hilliard, adviser Chris Klomp, and deputy Kyle Diamantas are guiding the transition.
Data & Statistics
Hoeg is the fifth CDER chief in 15 months; Makary served 13 months. Thousands of career staff left, and six senior FDA officials—including two CDER heads—departed within a year.
Why It Matters
The turnover arrives while the FDA confronts criticism over drug-approval consistency, vaccine-schedule changes, and alleged political interference, prompting concerns about public confidence and the agency’s future policy direction.
Official Statements & Responses
HHS spokeswoman Emily Hilliard said the agency “does not comment on personnel matters.” Trump called Makary “a great doctor” who “was having some difficulties.” Kennedy praised Makary’s “critical reforms” for the “Make America Healthy Again” agenda.
Criticism & Opposition
Anti-abortion groups demanded Makary’s removal over mifepristone, while vaping firms accused him of blocking flavored e-cigarettes. Industry leaders decried inconsistent drug-review standards, citing the FDA’s rejection of Replimune’s melanoma therapy.
Conflicting Reports & Gaps
Sources differ on Hoeg’s exit: Reuters reports she is “expected to leave,” whereas the New York Times quotes Hoeg stating she was “fired” and unaware of who ordered it. No definitive explanation for the departure has been provided by HHS.
Verbatim Quotes
- “HHS and FDA do not comment on personnel matters,” — Emily Hilliard, HHS spokesperson
- “I am incredibly proud of the work we were doing,” — Dr. Tracy Beth Hoeg, acting CDER director
- “I’m glad that we didn’t give in to any pressures to approve drugs when it wasn’t appropriate.” — Dr. Tracy Beth Hoeg
- “He was having some difficulties,” — Donald Trump, President of the United States
- “You pushed forward critical reforms and helped advance our mission to Make America Healthy Again,” — Robert F. Kennedy Jr., HHS Secretary
What’s Next
Kyle Diamantas will lead the FDA in an acting capacity while the White House vets permanent nominees. Michael Davis will steer CDER, and senior officials such as Chris Klomp are expected to shape forthcoming vaccine-policy and drug-review reforms.
